SavedAdd your journal

Journals / Marmara Medical Journal / 2011 / Cilt: 24 - Sayı: 1

-

Paraoksonaz-1 Enzimi ve Koroner Kalp Hastalıkları ile İlişkisi

Özlem TARÇIN
Pages
59–63
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Abstract

-

Özet

Anti-oksidan bir enzim olan paraoksonaz-1(PON1) enzim düzeyi ve aktivitesi, koroner arter hastalığı ile ilişkili olan hipertansiyon, diyabet, hiperlipidemi ve sigara kullanımı ile azalmaktadır. Tüm çalışmalar anjiografik olarak koroner arter hastalığı(KAH) kanıtlanmış olan hastalarda PON1 düzeyinin düştüğünü göstermektedir. Ancak polimorfizm açısından net olarak tek bir polimorfizm ile ilişkisi gösterilememiştir. Bu bilgilerin ışığında PON1 enzim düzeyi, KAH gelişimi açısından belirleyici bir marker olabilir. Ancak bunun klinik olarak kanıtlanması için prospektif ve kontrollü çalışmalara ihtiyaç vardır.Anahtar Kelimeler: Paraoksonaz-1, Koroner kalp hastalıkları, PON1 polimorfizm

🔖

Cite This Article

TARÇIN, Ö. (2011). -. Marmara Medical Journal, Cilt: 24 - Sayı: 1, 59–63. https://ajindex.com/articles/284032

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-507. doi: 1006/geno.1996.0225 Mackness MI, Hallam SD, Peard T, Warner S, Walker CH. The separation of sheep and human serum “A”-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp Biochem Physiol B 1985;82:675-677.
  2. Reddy ST, Wadleigh DJ, Grijalva V, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001;21:542-547.
  3. Mochizuki H, Scherer SW, Xi T,et al. Human PON2 gene at 7q21.3:cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 1998;213:149-157. doi: 10.1016/S0378- (98)00193-0
  4. Costa LG, Vitalone A, Cole TB, et al. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol;69: 541-550. doi: 10.1016/j.bcp.22004.08.027 Mueller RF, Hornung S, Furlong CE, Anderson J, Giblett ER, Motulsky AG. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical and linkage studies. Am J Hum Genet 1983;35:393-408.
  5. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, et al. Expression of human paraoxonase (PON1) during development. Pharmacogenetics 2003;13:1-8. do.: 1097/00008571-200306000-00007
  6. Augustinsson KB, Barr M. Age variation in plasma arylesterase activity in children. Clin Chim Acta;8:568-573. doi: 10.1016/0009-8981(63)90106- - Ecobichon DJ, Stephens DS. Perinatal development of human blood esterases. Clin Pharmacol Ther 1973;14:41-47. de Roos NM, Schouten EG, Scheek LM, van Tol A, Katan MB. Replacement of dietary saturated fat with trans fat reduces serum paraoxonase activity in healthy men and women. Metabolism;51:1534-1537. doi: 10.1053/meta.2002.36305 Wallace AJ, Sutherland WHF, Mann JI, Williams SM. The effect of meals rich in thermally stressed olive and safflower oils on post-prandial serum paraoxonase activity in patients with diabetes. Eur J Clin Nutr 2001;55:951-958.
  7. Deakin SP, James RW. Genetic and enviromental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clinical Science 2004;107: 435-447. doi: 1042/CS20040187 Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in lowdensity lipoprotein. FEBS Lett. 1991;286(1-2):152- doi: 10.1016//0014-5793(91)80962-3
  8. Gordon T, Castelli WP, Hjortlan